AR044603A1 - Proteinas quimericas aisladas de lumazina sintetasa modificada para la presentacion multiple de moleculas y sus aplicaciones - Google Patents

Proteinas quimericas aisladas de lumazina sintetasa modificada para la presentacion multiple de moleculas y sus aplicaciones

Info

Publication number
AR044603A1
AR044603A1 ARP040101923A ARP040101923A AR044603A1 AR 044603 A1 AR044603 A1 AR 044603A1 AR P040101923 A ARP040101923 A AR P040101923A AR P040101923 A ARP040101923 A AR P040101923A AR 044603 A1 AR044603 A1 AR 044603A1
Authority
AR
Argentina
Prior art keywords
chimeric proteins
lumazine
proteins
synthetase
antibodies
Prior art date
Application number
ARP040101923A
Other languages
English (en)
Inventor
F A Goldbaum
D A Lapagne
P Craig
P M Berguer
N Ainciart
Carlos Alberto Fossati
C A Velikovsky
J Cassataro
V Zylberman
G Giambartolomei
Original Assignee
Consejo Nac Invest Cient Tec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Nac Invest Cient Tec filed Critical Consejo Nac Invest Cient Tec
Priority to ARP040101923A priority Critical patent/AR044603A1/es
Priority to ES05760780T priority patent/ES2413159T3/es
Priority to PCT/US2005/019289 priority patent/WO2005121330A2/en
Priority to CN200580026046XA priority patent/CN101133163B/zh
Priority to US11/569,957 priority patent/US8685670B2/en
Priority to MXPA06013984A priority patent/MXPA06013984A/es
Priority to DK05760780.6T priority patent/DK1776456T3/da
Priority to EP05760780A priority patent/EP1776456B1/en
Priority to CA2569401A priority patent/CA2569401C/en
Priority to BRPI0511793A priority patent/BRPI0511793B8/pt
Publication of AR044603A1 publication Critical patent/AR044603A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
    • C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
    • C12Y205/01009—Riboflavin synthase (2.5.1.9)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Proteínas quiméricas conteniendo hasta diez copias de péptidos, polipéptidos o dominios proteicos insertados en los extremos amino terminales de la enzima lumazina sintetasa de Brucella spp. Las secuencias aisladas de nucleótidos que codifican para dichas proteínas quiméricas. Los vectores, plásmidos y células transformadas utilizados para expresar dichas proteínas quiméricas. Los anticuerpos monoclonales y policlonales producidos por dichas proteínas quiméricas. Los hibridomas productores de dichos anticuerpos. Las vacunas y composiciones farmacéuticas que contienen dichas proteínas quiméricas, secuencias de nucleótidos y anticuerpos. Un método para inducir respuesta inmune en organismos superiores que incluye la administración de cantidades efectivas de dichas vacunas y composiciones farmacéuticas. Biosensores que incluyen dichas proteínas quiméricas. Conjugados proteicos conformados por dichas proteínas quiméricas y un ligando unidos mediante enlaces covalentes y no covalentes. Los usos de dichas proteínas quiméricas, secuencias de nucleótidos, vectores, plásmidos, células transformadas, anticuerpos, hibridomas conjugados, biosensores, vacunas y composiciones farmacéuticas. La estructura cuaternaria de dichas proteínas quiméricas. Los péptidos, polipéptidos y proteínas insertados se expresan en diez copias sobre la proteína lumazina sintetasa de Brucella spp. Se generan de esa manera proteínas quiméricas que presentan péptidos en forma ordenada en el espacio, en los vértices de dos planos pentagonales y separados por una distancia regular de 40 Angtron. Su campo de aplicación es la producción de inmunógenos, vacunas, antisueros, anticuerpos monoclonales y reactivos de diagnósticos. Biosensores. Reivindicación 1: Proteínas quiméricas aisladas de lumazina sintetasa modificada para actuar como transporte múltiple de péptidos, y sus aplicaciones, dichas proteínas caracterizadas porque comprenden un péptido, polipéptido conectados a una proteína mutada de lumazina sintetasa de Brucella spp. cuya secuencia de nucleótidos codificante para sus primeros 8 residuos N-terminales ha sido modificada para permitir su corte por enzimas de restricción que no cortan naturalmente a la secuencia de nucleótidos codificante para la proteína nativa lumazina sintetasa de Brucella spp.
ARP040101923A 2004-06-03 2004-06-03 Proteinas quimericas aisladas de lumazina sintetasa modificada para la presentacion multiple de moleculas y sus aplicaciones AR044603A1 (es)

Priority Applications (10)

Application Number Priority Date Filing Date Title
ARP040101923A AR044603A1 (es) 2004-06-03 2004-06-03 Proteinas quimericas aisladas de lumazina sintetasa modificada para la presentacion multiple de moleculas y sus aplicaciones
ES05760780T ES2413159T3 (es) 2004-06-03 2005-06-03 Proteínas quiméricas aisladas de lumazina sintetasa modificada
PCT/US2005/019289 WO2005121330A2 (en) 2004-06-03 2005-06-03 Isolated chimeric proteins of modified lumazine synthase
CN200580026046XA CN101133163B (zh) 2004-06-03 2005-06-03 修饰的2，4-二氧四氢蝶啶合酶的分离的嵌合蛋白
US11/569,957 US8685670B2 (en) 2004-06-03 2005-06-03 Isolated chimeric proteins of modified lumazine synthase
MXPA06013984A MXPA06013984A (es) 2004-06-03 2005-06-03 Proteinas quimericas aisladas de lumazina sintetasa modificada.
DK05760780.6T DK1776456T3 (da) 2004-06-03 2005-06-03 Isolerede kimærisk proteiner af modificeret lumazin syntase
EP05760780A EP1776456B1 (en) 2004-06-03 2005-06-03 Isolated chimeric proteins of modified lumazine synthase
CA2569401A CA2569401C (en) 2004-06-03 2005-06-03 Isolated chimeric proteins of modified lumazine synthase
BRPI0511793A BRPI0511793B8 (pt) 2004-06-03 2005-06-03 proteínas quiméricas isoladas de lumazina sintase modificada

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP040101923A AR044603A1 (es) 2004-06-03 2004-06-03 Proteinas quimericas aisladas de lumazina sintetasa modificada para la presentacion multiple de moleculas y sus aplicaciones

Publications (1)

Publication Number Publication Date
AR044603A1 true AR044603A1 (es) 2005-09-21

Family

ID=35503729

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101923A AR044603A1 (es) 2004-06-03 2004-06-03 Proteinas quimericas aisladas de lumazina sintetasa modificada para la presentacion multiple de moleculas y sus aplicaciones

Country Status (10)

Country Link
US (1) US8685670B2 (es)
EP (1) EP1776456B1 (es)
CN (1) CN101133163B (es)
AR (1) AR044603A1 (es)
BR (1) BRPI0511793B8 (es)
CA (1) CA2569401C (es)
DK (1) DK1776456T3 (es)
ES (1) ES2413159T3 (es)
MX (1) MXPA06013984A (es)
WO (1) WO2005121330A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3003348B1 (en) 2013-05-27 2019-07-10 Inmunova S.A. Chimeras of brucella lumazine synthase and beta subunit of ab5 toxins
WO2017066484A2 (en) * 2015-10-13 2017-04-20 Carter Daniel C Nsp10 self-assembling fusion proteins for vaccines, therapeutics, diagnostics and other nanomaterial applications
KR20180132742A (ko) * 2016-04-11 2018-12-12 바이오제네시스 바고 우루과이 에스.에이. 바이러스 질환을 위한 범용 백신
CN106636138A (zh) * 2017-01-12 2017-05-10 李增魁 一种针对羊种3型布鲁氏菌感染的dna疫苗及其制备方法
CN112996819A (zh) * 2018-08-16 2021-06-18 纪念斯隆-凯特琳癌症中心 细胞分选系统及使用方法
EP4004018A1 (en) 2019-07-24 2022-06-01 GlaxoSmithKline Biologicals SA Modified human cytomegalovirus proteins
CN110922488A (zh) * 2019-11-08 2020-03-27 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种含EB病毒gp350的自组装纳米颗粒及制备方法和应用
CN111217918B (zh) * 2020-03-04 2020-11-10 中山大学 一种基于2,4-二氧四氢喋啶合酶的新型冠状病毒s蛋白双区域亚单位纳米疫苗
EP4161570A1 (en) 2020-06-05 2023-04-12 GlaxoSmithKline Biologicals S.A. Modified betacoronavirus spike proteins
CN114621352B (zh) * 2020-12-10 2024-01-23 中国科学院大连化学物理研究所 硅融合蛋白及制备和应用
CN112458054B (zh) * 2020-12-25 2023-03-31 上海纳米技术及应用国家工程研究中心有限公司 一种快速扩增体外nk细胞的方法
WO2023144665A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4258029A (en) 1979-04-23 1981-03-24 Connaught Laboratories Limited Synthetic adjuvants for stimulation of antigenic responses
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ512456A (en) 1998-11-30 2003-10-31 Cytos Biotechnology Ag Ordered molecular presentation of antigens
DE19910102B4 (de) * 1999-03-08 2006-06-01 Fischer, Markus, Dr.rer.nat. Proteinkonjugate, Verfahren, Vektoren, Proteine und DNA zu deren Herstellung, deren Verwendung, sowie Arzneimittel und Impfstoffe mit einem Gehalt derselben
US20040014158A1 (en) * 1999-03-08 2004-01-22 Adelbert Bacher Protein conjugates, methods, vectors, proteins and DNA for producing them, their use, and medicaments and vaccines containing a certain quantity of said protein conjugates
GB9929151D0 (en) 1999-12-09 2000-02-02 Univ Cambridge Tech Peptide and polypeptide display
WO2001085208A2 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
US20040213808A1 (en) * 2002-12-11 2004-10-28 Michael Lieberman Recombinant vaccine against flavivirus infection

Also Published As

Publication number Publication date
CN101133163A (zh) 2008-02-27
CA2569401A1 (en) 2005-12-22
US20090087435A1 (en) 2009-04-02
BRPI0511793B8 (pt) 2021-05-25
MXPA06013984A (es) 2007-03-01
WO2005121330A2 (en) 2005-12-22
CN101133163B (zh) 2013-04-24
WO2005121330A3 (en) 2007-11-01
US8685670B2 (en) 2014-04-01
BRPI0511793A (pt) 2008-01-15
ES2413159T3 (es) 2013-07-15
EP1776456B1 (en) 2013-02-20
BRPI0511793B1 (pt) 2018-10-23
EP1776456A2 (en) 2007-04-25
CA2569401C (en) 2017-03-07
DK1776456T3 (da) 2013-05-27
EP1776456A4 (en) 2008-06-18

Similar Documents

Publication Publication Date Title
van der Does et al. Interaction between SecA and SecYEG in micellar solution and formation of the membrane-inserted state
ES2916101T3 (es) Nuevas proteínas de unión a inmunoglobulina y su uso en la purificación por afinidad
CN111133002B (zh) 具有高体内耐受性的基于蒽环类药的抗体药物缀合物
HRP20190799T1 (hr) Imunocitokini na bazi il-15 i sushi domene il-15r alfa
Eberle et al. Identification and characterization of a novel human plant pathogenesis-related protein that localizes to lipid-enriched microdomains in the Golgi complex
BRPI0511793A (pt) proteìnas quiméricas isoladas de lumazina sintase modificada
ATE353965T1 (de) An g-protein gekoppelte rezeptoren und deren verwendungen
Aslam et al. The Calmodulin-like calcium binding protein EhCaBP3 of Entamoeba histolytica regulates phagocytosis and is involved in actin dynamics
ES2779977T3 (es) Anticuerpos monoclonales inmunoestimuladores contra interleucina 2 humana
AR047345A1 (es) Vacuna para mejorar el crecimiento de animales a base de epitopos neutralizantes
IL152886A0 (en) B-7 related nucleic acids and polypeptides and pharmaceutical compositions containing the same
ATE353365T1 (de) Neue b7-4 moleküle und deren verwendungen
EP1009752A4 (en) NOVEL TANGO-77 PROTEIN FAMILY MOLECULES AND USES THEREOF
JP2013511966A5 (es)
ATE419358T1 (de) Gebrauchsverfaheren eines neuen lysyloxidase- verwandten proteins
Tomé‐Amat et al. Production and characterization of scFvA33T1, an immunoRNase targeting colon cancer cells
EP2928915A1 (en) Fgf-10 complexes
Rinne et al. Targeting tumor cells overexpressing the human epidermal growth factor receptor 3 with potent drug conjugates based on affibody molecules
Gagné et al. Strategies for the production of isotopically labelled Fab fragments of therapeutic antibodies in Komagataella phaffii (Pichia pastoris) and Escherichia coli for NMR studies
WO2001061005A3 (en) Molecules of the pyrin domain protein family and uses thereof
Faber et al. Production, quality control, stability and pharmacotoxicity of a malaria vaccine comprising three highly similar PfAMA1 protein molecules to overcome antigenic variation
WO2005012532A1 (es) Sistema para la producción de proteínas diméricas basado en el sistema de transporte de hemolisina de escherichia coli
WO2002061049A3 (en) Novel molecules of the pyrin/nbs/lrr protein family and uses thereof
Fang et al. Immunogenicity of Recombinant Maltose-binding Protein (MBP)–Gonadotropin Releasing Hormone I (GnRH-I)
Loftis et al. An in vivo selection-derived D-peptide for engineering erythrocyte-binding antigens that promote immune tolerance

Legal Events

Date Code Title Description
FG Grant, registration